BioSpace

Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release.

By BioSpace

1 min read
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights